Literature DB >> 8561113

Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients.

O A Alvarez1, G A Lopera, V Patel, C E Encarnacion, J C Palmaz, M Lee.   

Abstract

Thrombocytopenia secondary to hypersplenism is a well-known complication of portal hypertension. The effects of transjugular intrahepatic portosystemic shunt (TIPS) on hypersplenism have not been adequately studied. In this report, we describe 11 patients who had significant improvement in their thrombocytopenia due to hypersplenism after TIPS. There was a statistically significant improvement in the platelet counts after TIPS placement, in virtually every case during the follow-up period, although some patients had platelet counts less than 100,000/mm3 at the end of the follow-up period. Statistically significant hemodynamic improvement in the gradient pressure was observed immediately after TIPS. Furthermore, all patients tolerated the procedure well, and TIPS-related complications were encountered during the follow-up period. Our data suggest that TIPS is an effective, noninvasive alternative to surgical interventions in the management of hypersplenism in cirrhotic patients, who are generally high-risk surgical candidates.

Entities:  

Mesh:

Year:  1996        PMID: 8561113

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Partial embolization as re-treatment of hypersplenism after unsuccessful splenic artery ligation.

Authors:  Zheng-Ju Xu; Lian-Qiu Zheng; Xing-Nan Pan
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.

Authors:  Ujjal Poddar; Upender Shava; Surender Kumar Yachha; Jaya Agarwal; Sheo Kumar; Sanjay S Baijal; Anshu Srivastava
Journal:  Hepatol Int       Date:  2014-09-23       Impact factor: 6.047

3.  Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?

Authors:  Moon Young Kim; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2015-01-25       Impact factor: 6.047

4.  Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation.

Authors:  J Goulis; T N Chau; S Jordan; A B Mehta; A Watkinson; K Rolles; A K Burroughs
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

5.  The Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis.

Authors:  Omar I Massoud; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

Review 6.  The use and misuse of transjugular intrahepatic portasystemic shunts.

Authors:  A J Sanyal
Journal:  Curr Gastroenterol Rep       Date:  2000-02

7.  Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.

Authors:  Z Karasu; A Gurakar; B Kerwin; S Hulagu; A Jazzar; R McFadden; B Nour; A Sebastian; F Cassidy; K Stokes; D H Van Thiel; H Wright
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

8.  Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C.

Authors:  Tetsuro Sekiguchi; Takeaki Nagamine; Hitoshi Takagi; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis.

Authors:  Elise J Barney; Ester C Little; Richard D Gerkin; Alberto X Ramos; Jeffrey Kahn; Mark Wong; Geetha Kolli; Richard Manch
Journal:  Dig Dis Sci       Date:  2012-05-16       Impact factor: 3.199

Review 10.  Management of thrombocytopenia in advanced liver disease.

Authors:  V G R Gangireddy; P C Kanneganti; S Sridhar; S Talla; T Coleman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.